Literature DB >> 8699221

Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression.

M E Berens1, M D Rief, J R Shapiro, D Haskett, A Giese, A Joy, S W Coons.   

Abstract

Astrocytic neoplasms show a high incidence of elevated or mutated epidermal growth factor receptor (EGFR) expression. Although proliferative effects from EGFR activation are well described, the role that changes in this receptor play in glioma growth and migration remain poorly addressed. This report characterizes changes in the levels of EGFR expression in three glial tumors at initial presentation (resection) and at the time of recurrence. By quantitative flow cytometry the mean level of EGFR expression increased, decreased, or remained the same in different recurrent astrocytomas relative to their primary tumor cells. Immunocytochemistry for EGFR on monolayer cells corroborated the level of expression in the recurrent tumors relative to their matched primary specimen. Immunoprecipitation indicated that 170 kd EGFR was expressed in each of the tumors, and showed normal down regulation following treatment with EGF. Proliferation response to EGF was seen in only 1/6 instances, but was concentration-dependent when observed. Stimulated migration of the cells was frequently seen and was also concentration-dependent on EGF; the magnitude of response was related to the relative level of 170 kd EGFR expression in the cells. EGFR immunostaining of tissue sections from the tumors confirmed the levels of EGFR expressed in primary and recurrent astrocytomas as was seen in the cultured cells. These results indicate that the relative levels of EGFR in early passage cell cultures from glioma specimens concurs with the measured tissue levels of expression. Human glioma cells are more responsive to migration induction than proliferation induction by EGF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699221     DOI: 10.1007/bf00146079

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  The incidence of interhemispheric extension of glioblastoma multiforme through the corpus callosum.

Authors:  H P MAXWELL
Journal:  J Neurosurg       Date:  1946-01       Impact factor: 5.115

2.  C6 glioma-astrocytoma cell and fetal astrocyte migration into artificial basement membrane: a permissive substrate for neural tumors but not fetal astrocytes.

Authors:  J J Bernstein; E R Laws; K V Levine; L R Wood; G Tadvalkar; W J Goldberg
Journal:  Neurosurgery       Date:  1991-05       Impact factor: 4.654

3.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

Authors:  A J Ekstrand; N Sugawa; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

4.  Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

Authors:  M Lund-Johansen; R Bjerkvig; P A Humphrey; S H Bigner; D D Bigner; O D Laerum
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

5.  Epidermal growth factor receptor in human brain tumors.

Authors:  A Di Carlo; A Mariano; P E Macchia; M C Moroni; L Beguinot; V Macchia
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

6.  Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

Authors:  S H Bigner; P A Humphrey; A J Wong; B Vogelstein; J Mark; H S Friedman; D D Bigner
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

7.  Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.

Authors:  M H Werner; P A Humphrey; D D Bigner; S H Bigner
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index.

Authors:  S W Coons; P C Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

9.  Amplification of the epidermal growth factor receptor gene in human gliomas.

Authors:  S H Torp; E Helseth; L Ryan; S Stølan; A Dalen; G Unsgaard
Journal:  Anticancer Res       Date:  1991 Nov-Dec       Impact factor: 2.480

10.  Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10.

Authors:  A E Karlbom; C D James; J Boethius; W K Cavenee; V P Collins; M Nordenskjöld; C Larsson
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

View more
  8 in total

Review 1.  "...those left behind." Biology and oncology of invasive glioma cells.

Authors:  M E Berens; A Giese
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

2.  Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10.

Authors:  Toshiyuki Murai; Takayuki Miyauchi; Toshio Yanagida; Yasushi Sako
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

3.  Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis.

Authors:  L Mariani; C Beaudry; W S McDonough; D B Hoelzinger; T Demuth; K R Ross; T Berens; S W Coons; G Watts; J M Trent; J S Wei; A Giese; M E Berens
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  Migration of human glioma cells in response to tumour cyst fluids.

Authors:  A Giese; F Schröder; A Steiner; M Westphal
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

5.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Authors:  Paul D Brown; Sunil Krishnan; Jann N Sarkaria; Wenting Wu; Kurt A Jaeckle; Joon H Uhm; Francois J Geoffroy; Robert Arusell; Gaspar Kitange; Robert B Jenkins; John W Kugler; Roscoe F Morton; Kendrith M Rowland; Paul Mischel; William H Yong; Bernd W Scheithauer; David Schiff; Caterina Giannini; Jan C Buckner
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

6.  Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.

Authors:  Yuduo Guo; Xin He; Mingshan Zhang; Yanming Qu; Chunyu Gu; Ming Ren; Haoran Wang; Weihai Ning; Junfa Li; Chunjiang Yu; Hongwei Zhang
Journal:  J Neurooncol       Date:  2020-03-13       Impact factor: 4.130

7.  Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.

Authors:  Luigi Catacuzzeno; Bernard Fioretti; Fabio Franciolini
Journal:  J Signal Transduct       Date:  2012-05-17

8.  Computational systems biology in cancer: modeling methods and applications.

Authors:  Wayne Materi; David S Wishart
Journal:  Gene Regul Syst Bio       Date:  2007-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.